Clinical Trial

TY-9591 in the Patients With EGFR Mutations in Advanced NSCLC With Brain Metastases

Recruiting Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated November 21, 2024 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
This study is to evaluate the efficacy and safety of TY-9591 in first-line treatment of patients with EGFR-sensitive mutation-positive non-small cell lung cancer with brain metastases compared to Osimertinib.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2023-07-09; most recent amendment 2024-11-18.
Status change: Not Yet Recruiting → Recruiting 2023-10-16
Trial Details
NCT Number NCT05948813
Lead Sponsor TYK Medicines, Inc
Conditions NSCLC, EGFR Activating Mutation, Brain Metastases
Enrollment 420 participants
Start Date 2023-08-17
Primary Completion 2025-06-30 (estimated)
Study Completion 2027-12-30 (estimated)
Updated on ClinicalTrials.gov 2024-11-21